CYBN Cybin Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
04:04
Jan 29
Jan 29
Undervalued psychedelic biotech with major catalysts
Cybin is developing psilocybin-based treatments CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder with evidence of rapid, durable remission (75% after two doses and about 70% still depression-free at 12 months), a much larger effect size than SSRIs, and mild, transient side effects. It is well funded after raising over $350 million, has a roughly $200 million market cap versus a typical $600–700 million valuation for its stage, and has catalysts including CYB004 Phase 2 data in Q2 2025, CYB003 Phase 3 results by late 2026/early 2027, an expected NDA filing in 2027, FDA breakthrough therapy designation, and improving regulatory/payer acceptance. Management views it as a rare large leap in drug development and a good value entry point.
HIGH
About CYBN Investor Commentary
Across the available history and selected sources, Buzzberg tracks CYBN (Cybin Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Doug Drysdale.